ETOPOSIDE PIERRE FABRE 100mg/5ml 20mg / ml perfusive solution concentrate medication leaflet

L01CB01 • etoposide • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Podophyllotoxin derivatives

Etoposide is a chemotherapy drug used to treat various types of cancer, including small cell lung cancer, testicular cancer, lymphomas, and leukemias. It belongs to a class of drugs called topoisomerase II inhibitors, which work by interfering with cell division, thereby destroying rapidly dividing cancer cells.

The mechanism of action of etoposide involves inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. By blocking this enzyme, etoposide causes the accumulation of DNA strand breaks, leading to cancer cell death. It is administered either intravenously or orally, depending on the type of cancer and the treatment protocol.

While effective, etoposide can cause side effects. The most common include nausea, vomiting, loss of appetite, hair loss, fatigue, and a decrease in blood cell counts (myelosuppression), which can increase the risk of infections, bleeding, and anemia. In rare cases, severe allergic reactions or other complications, such as secondary leukemia, may occur, especially with long-term use.

Etoposide must be administered under the strict supervision of an oncologist, and patients should be regularly monitored to assess their response to treatment and detect potential side effects. It is contraindicated in patients with hypersensitivity to the active substance or severe bone marrow suppression. During treatment, it is important for patients to avoid contact with sick individuals and follow their doctor's recommendations to minimize associated risks.